PH12022552748A1 - Crystalline ret inhibitor. - Google Patents
Crystalline ret inhibitor.Info
- Publication number
- PH12022552748A1 PH12022552748A1 PH1/2022/552748A PH12022552748A PH12022552748A1 PH 12022552748 A1 PH12022552748 A1 PH 12022552748A1 PH 12022552748 A PH12022552748 A PH 12022552748A PH 12022552748 A1 PH12022552748 A1 PH 12022552748A1
- Authority
- PH
- Philippines
- Prior art keywords
- crystalline
- ret inhibitor
- ret
- crystalline form
- diseases
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 229940125905 RET kinase inhibitor Drugs 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 abstract 1
- 229940121610 selpercatinib Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Semiconductor Lasers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011701P | 2020-04-17 | 2020-04-17 | |
| US202163151354P | 2021-02-19 | 2021-02-19 | |
| PCT/US2021/026611 WO2021211380A1 (en) | 2020-04-17 | 2021-04-09 | Crystalline ret inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552748A1 true PH12022552748A1 (en) | 2024-03-25 |
Family
ID=75747118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552748A PH12022552748A1 (en) | 2020-04-17 | 2021-04-09 | Crystalline ret inhibitor. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP4136090A1 (uk) |
| JP (2) | JP7608474B2 (uk) |
| KR (1) | KR20230002706A (uk) |
| CN (1) | CN115916791B (uk) |
| AU (1) | AU2021255488B2 (uk) |
| BR (1) | BR112022020446A2 (uk) |
| CA (1) | CA3174316A1 (uk) |
| CL (3) | CL2022002849A1 (uk) |
| CO (1) | CO2022014882A2 (uk) |
| CR (1) | CR20220520A (uk) |
| DO (1) | DOP2022000221A (uk) |
| EC (1) | ECSP22080982A (uk) |
| IL (1) | IL297212A (uk) |
| JO (1) | JOP20220263A1 (uk) |
| MX (1) | MX2022012952A (uk) |
| PE (1) | PE20230388A1 (uk) |
| PH (1) | PH12022552748A1 (uk) |
| TW (1) | TWI865765B (uk) |
| UA (1) | UA129813C2 (uk) |
| WO (1) | WO2021211380A1 (uk) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022069357A1 (en) * | 2020-10-01 | 2022-04-07 | Sandoz Ag | Crystalline form of selpercatinib |
| JP7835751B2 (ja) * | 2020-11-13 | 2026-03-25 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 二環系誘導体を含む阻害剤の遊離塩基の結晶及びその製造方法と使用 |
| KR20240101659A (ko) | 2021-12-13 | 2024-07-02 | 록쏘 온콜로지, 인코포레이티드 | 셀페르카티닙 ret 억제제의 결정질 형태 a 및 그의 제조 방법 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI783057B (zh) | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法 |
| TWI876442B (zh) * | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| US20210379056A1 (en) * | 2018-09-30 | 2021-12-09 | Applied Pharmaceutical Science, Inc. | Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof |
| CN111004257B (zh) * | 2019-12-24 | 2021-06-29 | 武汉九州钰民医药科技有限公司 | 制备RET抑制剂Selpercatinib的方法 |
-
2021
- 2021-04-07 TW TW110112512A patent/TWI865765B/zh active
- 2021-04-09 EP EP21722702.4A patent/EP4136090A1/en active Pending
- 2021-04-09 IL IL297212A patent/IL297212A/en unknown
- 2021-04-09 MX MX2022012952A patent/MX2022012952A/es unknown
- 2021-04-09 AU AU2021255488A patent/AU2021255488B2/en active Active
- 2021-04-09 PE PE2022002417A patent/PE20230388A1/es unknown
- 2021-04-09 CN CN202180043101.5A patent/CN115916791B/zh active Active
- 2021-04-09 KR KR1020227039684A patent/KR20230002706A/ko active Pending
- 2021-04-09 BR BR112022020446A patent/BR112022020446A2/pt unknown
- 2021-04-09 JP JP2022562612A patent/JP7608474B2/ja active Active
- 2021-04-09 WO PCT/US2021/026611 patent/WO2021211380A1/en not_active Ceased
- 2021-04-09 CR CR20220520A patent/CR20220520A/es unknown
- 2021-04-09 UA UAA202203805A patent/UA129813C2/uk unknown
- 2021-04-09 PH PH1/2022/552748A patent/PH12022552748A1/en unknown
- 2021-04-09 CA CA3174316A patent/CA3174316A1/en active Pending
-
2022
- 2022-10-14 CL CL2022002849A patent/CL2022002849A1/es unknown
- 2022-10-16 JO JOJO/P/2022/0263A patent/JOP20220263A1/ar unknown
- 2022-10-17 DO DO2022000221A patent/DOP2022000221A/es unknown
- 2022-10-17 EC ECSENADI202280982A patent/ECSP22080982A/es unknown
- 2022-10-19 CO CONC2022/0014882A patent/CO2022014882A2/es unknown
-
2024
- 2024-09-30 CL CL2024002943A patent/CL2024002943A1/es unknown
- 2024-09-30 CL CL2024002944A patent/CL2024002944A1/es unknown
- 2024-10-10 JP JP2024177871A patent/JP7851375B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024002943A1 (es) | 2025-05-30 |
| CL2024002944A1 (es) | 2025-04-04 |
| NZ793376A (en) | 2025-10-31 |
| JP7851375B2 (ja) | 2026-04-24 |
| JP2023522012A (ja) | 2023-05-26 |
| CR20220520A (es) | 2022-11-15 |
| WO2021211380A1 (en) | 2021-10-21 |
| UA129813C2 (uk) | 2025-08-06 |
| MX2022012952A (es) | 2023-01-11 |
| JOP20220263A1 (ar) | 2022-10-16 |
| TW202202501A (zh) | 2022-01-16 |
| AU2021255488B2 (en) | 2024-05-30 |
| KR20230002706A (ko) | 2023-01-05 |
| AU2021255488A1 (en) | 2022-11-10 |
| ECSP22080982A (es) | 2023-01-31 |
| CN115916791B (zh) | 2025-09-05 |
| IL297212A (en) | 2022-12-01 |
| CA3174316A1 (en) | 2021-10-21 |
| EP4136090A1 (en) | 2023-02-22 |
| CO2022014882A2 (es) | 2022-10-31 |
| CL2022002849A1 (es) | 2023-06-16 |
| JP2025020140A (ja) | 2025-02-12 |
| CN115916791A (zh) | 2023-04-04 |
| JP7608474B2 (ja) | 2025-01-06 |
| PE20230388A1 (es) | 2023-03-06 |
| DOP2022000221A (es) | 2023-01-15 |
| BR112022020446A2 (pt) | 2022-11-29 |
| TWI865765B (zh) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552748A1 (en) | Crystalline ret inhibitor. | |
| ZA202212876B (en) | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders | |
| SA519401541B1 (ar) | [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات | |
| PH12021500017A1 (en) | Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| MX2022010425A (es) | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. | |
| IL286636A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| TN2019000107A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| WO2019209962A8 (en) | Compounds and uses thereof | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| WO2019209948A8 (en) | Compounds and uses thereof | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| GB202416189D0 (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| WO2020154571A8 (en) | Compounds and uses thereof | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| CL2024000776A1 (es) | Milvexian para la prevención y el tratamiento de trastornos tromboembólicos | |
| PH12023552792A1 (en) | Combination therapies for the treatment of cancer | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| EP4090736A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT, RELIEF AND/OR PREVENTION OF ILLNESSES OR DISORDERS ASSOCIATED WITH DNASE1 AND/OR DNASE1L3 DEFICIENCY | |
| ZA202310169B (en) | Cocrystalline forms of a bruton's tyrosine kinase inhibitor | |
| MX2022010456A (es) | Compuestos heterocíclicos para modular la subfamilia de receptores nucleares 2, grupo f, miembro 6. | |
| PH12021551590A1 (en) | Quinoline compounds as inhibitors of tam and met kinases | |
| EP4461362A3 (en) | Nk1-antagonist combination and method for treating synucleinopathies |